[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100388385":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":21,"responsibleParty":42,"collaborators":7,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":7,"eligibilityCriteria":49,"healthyVolunteers":46,"sex":50,"minAge":51,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":7,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Matrix Biomed, Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","MBM-02 (Tempol)","Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.",[14],"Tempol; 4-hydroxy-tempo; 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Benji Crane","CONTACT","16264376506","bjcrane@matrixbiomed.com",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Prostate Oncology Specialists","AVAILABLE","Marina del Rey","California","90292","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-118.45371,33.98162,{"lat":34,"lon":33},[37,39],{"name":38,"role":18,"phone":7,"phoneExt":7,"email":7},"Krista Yasuda",{"name":40,"role":41,"phone":7,"phoneExt":7,"email":7},"Mark Scholz, MD","PRINCIPAL_INVESTIGATOR",{"type":43,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100388385","a-single-patient-compassionate-use-of-mbm-02-tempol-for-the-treatment-of-prostate-cancer-100388385",false,"NCT04337099","A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer","Inclusion Criteria:\n\n* Biochemical Recurrent Prostate Cancer\n\nExclusion Criteria:\n\n\\-","MALE","18 Years","EXPANDED_ACCESS","A single patient compassionate use clinical trial for the use of MBM-02 (TEMPOL) for the treatment of prostate cancer. The single patient will be exposed to orally administered TEMPOL for up to 12 months at a maximum total daily dose of 800mg.",[55],"Prostate Cancer","2021-05-03",{"date":58,"type":59},"2021-05-05","ACTUAL",{"name":5,"class":6},1]